Borean to Present at the 14th Annual Euro-Biotech Forum, June 26-28 in Paris.AARHUS, Denmark -- Borean Pharma ApS, the Danish biopharmaceutical and protein engineering company, announced today that it will be presenting at Windhover's 14th Annual Euro-Biotech Forum 2007 on Wednesday, June 27 in Paris. The Euro-Biotech Forum is being held at The Westin Paris Hotel in Paris, France, June 26-28, 2007. Johanna Holldack, the CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Borean Pharma, will provide an overview of the Company's progress and an update on recent and upcoming scientific developments. Dr Holldack will also expand on the company's Platform technology, based on the only scaffold that induces complement lysis lysis /ly·sis/ (li´sis) 1. destruction or decomposition, as of a cell or other substance, under influence of a specific agent. 2. mobilization of an organ by division of restraining adhesions. 3. and has tumour killing potential, and the strong portfolio of therapeutic projects. The talk takes place at 4:35 pm on the 27th of June. The 14th Annual Euro-Biotech Forum is the industry's most upscale and efficient partnering meeting for American and European life science companies. Windhover wind·hov·er n. Chiefly British A kestrel. hand-picks the presenting companies to ensure they represent the most exciting partnering candidates available and a nice balance of opportunities across therapeutic categories, product types and geographies. About Borean Pharma: Borean Pharma was established with the objective to develop a new generation of pharmaceutical protein products. The Company's competitive advantage lies in its proprietary technology, enabling it to develop a new generation of highly efficacious compounds and antibody analogues. Based on the tetranectin antibody molecule, Borean has derived a vast library of proteins with potential therapeutic applications. In addition, through a process of trimerisation, Borean can enhance the efficacy and stability of these proteins, greatly increasing their effectiveness in a therapeutic setting. In addition, the ease of production in E.coli addresses a major shortcoming short·com·ing n. A deficiency; a flaw. shortcoming Noun a fault or weakness Noun 1. of monoclonal antibodies. Borean has five product programmes, one of which has been acquired by Roche, targeting atherosclerosis, rheumatoid arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. , Crohn's disease Crohn's disease: see colitis. and cancer and a number of discovery programmes. The Company believes that it can unleash the true potential of biopharmaceuticals by providing efficacious and cost-effective protein-based antibody analogues. The two main components of Borean's technology platform are its CTLD CTLD Country Top-Level Domain CTLD Churches Together in Lincoln and District CTLD Controller Description library technology and a trimerisation technology. In addition, the Company has a broad set of supporting tools that cover key elements from research to product development, including the cost efficient E. coli E. coli: see Escherichia coli. E. coli in full Escherichia coli Species of bacterium that inhabits the stomach and intestines. E. coli can be transmitted by water, milk, food, or flies and other insects. based production of the final products. For more information: www.boreanpharma.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion